Article
PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer.
Clinical colorectal cancer - 1 Jun 2012
Sood Arjun, McClain Danielle, Maitra Radhashree, Basu-Mallick Atrayee, Seetharam Raviraja, Kaubisch Andreas, Rajdev Lakshmi, Mariadason John M, Tanaka Kathryn, Goel Sanjay
Abstract excerpt
PURPOSE: To identify novel genetic markers predictive of clinical benefit from epidermal growth factor receptor-directed antibody therapy in patients with metastatic colorectal cancer. PATIENTS AND METHODS: Seventy-six consecutive patients who received cetuximab or panitumumab, either alone or in combination with chemotherapy and with available tumor tissue were included. Tumor tissue was tested by pyrosequencing...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.